Initial feasibility cohort of temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade intracranial malignancies

• Published in: Scientific reports Vol. 14; no. 1; pp. 26685 - 12
• Main Authors: La Rosa, Alonso, Fellows, Zachary, Wroe, Andrew J., Coutinho, Len, Pons, Eduardo, McAllister, Nicole C., Tolakanahalli, Ranjini, Kutuk, Tugce, Hall, Matthew D., Press, Robert H., McDermott, Michael W., Odia, Yazmin, Ahluwalia, Manmeet S., Mehta, Minesh P., Gutierrez, Alonso N., Kotecha, Rupesh
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04-11-2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4028; 692/4028/67; Central nervous system; CNS malignancies; Early experience; Humanities and Social Sciences; Irradiation; Malignancy; multidisciplinary; Pulsed-reduced dose rate; Radiation therapy; Recurrence/progression; Science; Science (multidisciplinary); Temporally modulated proton re-irradiation; Toxicity; CNS malignancies; Recurrence/progression; Pulsed-reduced dose rate; Temporally modulated proton re-irradiation
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-78370-x

Recurrent high-grade intracranial malignancies have a grim prognosis and uniform management guidelines are lacking. Re-irradiation is underused due to concerns about irreversible side effects. Pulsed-reduced dose rate radiotherapy (PRDR) aims to reduce toxicity while improving tumor control by exploiting dose-rate effects. We share our initial experience with temporally modulated pulsed proton re-irradiation (TMPPR), focusing on workflow, safety, feasibility, and outcomes for the first patient cohort. TMPPR was administered to patients with recurrent or progressive central nervous system malignancies using intensity modulated proton therapy with three fields. Patient and treatment data were collected, responses categorized using RANO assessment, and toxicities graded using CTCAE v5.0. Five patients received TMPPR between October 2022 and May 2023, with a median age of 54 years (Range: 32–72), and a median time from initial radiotherapy to re-RT of 23 months (Range 14–40). Treatment was completed without delay, with a median dose of 60 GyRBE in 30 fractions. Initial treatment response assessment showed complete (n = 1) or partial (n = 3) responses. Limited toxicity was observed, primarily grade 2 alopecia and one case of radiation necrosis graded at 2. This early experience demonstrates the feasibility of TMPPR delivery, highlighting the importance of prospective evaluations in the re-irradiation setting.